Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia are safe, of high quality, and effective for their intended purpose. This Act fills the gap by regulating the manufacture, supply, and advertising of therapeutic goods, thus protecting public health by ensuring that only goods that meet certain standards are available to the public. The Therapeutic Goods Administration, which operates under the auspices of the Department of Health, is the enforcing body responsible for implementing the provisions of the Act. The policy objective of the Act is to safeguard the health and safety of the Australian population by controlling the therapeutic goods market. This is achieved by licensing manufacturers, monitoring the quality of therapeutic goods, and ensuring compliance with safety standards. This gazette serves as a public record of licences granted to specific companies, thereby enhancing transparency and accountability in the manufacturing of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Department of Health, provides a framework for the regulation of therapeutic goods in Australia. This Act applies to various entities involved in the manufacture, importation, supply, and advertising of therapeutic goods. The legislation covers a wide range of products including medicines, medical devices, blood, and tissues, and it mandates that entities must hold appropriate licences and permits to operate within these sectors. The Act applies across the Commonwealth, thereby ensuring a uniform approach to the regulation of therapeutic goods throughout Australia. The legislation provides for specific exclusions and exemptions, such as for research purposes or under certain conditions for personal use, which are detailed within the Act itself or in subordinate instruments. Additionally, the Act can extend or restrict its application through regulations and guidelines issued by the TGA, thereby providing flexibility and specificity in its enforcement. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods, such as the ones issued to Vitex Pharmaceuticals Pty Ltd, BJP Laboratories Pty Ltd, Australian Pharmaceutical Manufacturers Pty Ltd, and GMP Pharmaceuticals Pty Limited, exemplifies the Act's role in maintaining oversight and ensuring compliance within the therapeutic goods industry.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") is an important piece of legislation that regulates the manufacturing, distribution, and sale of therapeutic goods in Australia. Section 38 of the Act allows the Secretary of the Department of Health to grant a licence to manufacture therapeutic goods to an entity that meets the requirements set out in the Act and its regulations. The publication of the list of manufacturers granted such a licence is a key provision of the Act (s.38), as it provides transparency and public access to information about which entities are authorised to manufacture therapeutic goods. The recent publication lists four companies that have been granted a licence: Vitex Pharmaceuticals Pty Ltd (Licence No. MI-2015-LI-11255-1), BJP Laboratories Pty Ltd (Licence No. MI-2017-LI-02305-1), Australian Pharmaceutical Manufacturers Pty Ltd (Licence No. MI-2017-LI-08681-1), and GMP Pharmaceuticals Pty Limited (Licence No. MI-2016-LI-12063-1). The Act imposes several obligations and requirements on the entities that have been granted a licence to manufacture therapeutic goods. These obligations include ensuring that the therapeutic goods they manufacture meet the standards set out in the Act and its regulations, maintaining records of the manufacture and distribution of the goods, and complying with any conditions or requirements imposed by the Secretary. The licensed manufacturers must also ensure that their manufacturing processes and facilities meet the necessary quality and safety standards. These obligations are designed to ensure that therapeutic goods available in the Australian market are safe, of high quality, and effective for their intended use. Failure to comply with the requirements of the Act and its regulations can result in a range of consequences, including the suspension or cancellation of a licence to manufacture therapeutic goods. Section 39 of the Act allows the Secretary to suspend or cancel a licence if the Secretary is satisfied that the licence holder has contravened any provision of the Act or its regulations, or if the licence holder is otherwise unfit to hold a licence. Additionally, under Section 119 of the Act, it is an offence to manufacture therapeutic goods without a valid licence, and such an offence is punishable by a fine of up to $1,215,000 for a corporation and/or imprisonment for up to five years. These penalties serve as a deterrent to non-compliance and ensure that only entities that meet the necessary standards are allowed to manufacture therapeutic goods in Australia.